Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
A major clinical trial of the Galleri multi-cancer blood test involving over 142,000 NHS patients has failed to meet its primary goal of reducing late-stage cancer diagnoses. The study, presented at an oncology conference, showed no statistically significant difference in advanced cancer detection between those who received the Galleri test and those who did not. While some secondary findings were noted, experts remain cautious about the implications of the results.
- ▪The trial involved 142,942 participants aged 50 to 77 with no cancer symptoms.
- ▪Results indicated that the Galleri test did not statistically reduce late-stage cancer diagnoses compared to standard screening alone.
- ▪Some secondary findings suggested a potential reduction in stage four cancers, but the primary endpoint was not met.
Opening excerpt (first ~120 words) tap to expand
The trial enrolled 142,942 people with no cancer symptoms. Each had blood drawn once a year for three years and received the recommended cancer screening tests, half having the Galleri test. Photograph: NHS England & NHS Improvement/PAView image in fullscreenThe trial enrolled 142,942 people with no cancer symptoms. Each had blood drawn once a year for three years and received the recommended cancer screening tests, half having the Galleri test. Photograph: NHS England & NHS Improvement/PACancer researchTrial of multi-cancer blood test among 142,000 NHS patients fails to meet main aimResults presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnosesAndrew Gregory Health editor, in ChicagoSat 30 May 2026 08.16 EDTLast modified on Sat 30 May…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — World.
Discussion
0 commentsMore from The Guardian — World
